Ranibizumab 0.5 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proliferative Diabetic Retinopathy (PDR)
Conditions
Proliferative Diabetic Retinopathy (PDR)
Trial Timeline
Dec 11, 2012 → Dec 5, 2017
NCT ID
NCT01594281About Ranibizumab 0.5 mg
Ranibizumab 0.5 mg is a phase 2 stage product being developed by Novartis for Proliferative Diabetic Retinopathy (PDR). The current trial status is completed. This product is registered under clinical trial identifier NCT01594281. Target conditions include Proliferative Diabetic Retinopathy (PDR).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02366468 | Approved | Completed |
| NCT01976312 | Phase 3 | Completed |
| NCT01976338 | Phase 3 | Completed |
| NCT01594281 | Phase 2 | Completed |
| NCT01148511 | Approved | Completed |
| NCT00826371 | Phase 3 | Completed |
Competing Products
20 competing products in Proliferative Diabetic Retinopathy (PDR)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| LY2784544 | Eli Lilly | Phase 1 | 33 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| Epcoritamab | AbbVie | Phase 1 | 33 |
| Brolucizumab 6 mg | Novartis | Phase 3 | 77 |
| CANAKINUMAB (ILARIS®) | Novartis | Phase 1 | 33 |
| Lucentis | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Octreotide, 30 mg i.m. LAR formulation | Novartis | Phase 3 | 77 |
| AUY922 | Novartis | Phase 2 | 52 |
| Lucentis | Roche | Pre-clinical | 23 |
| Macugen (pegaptanib) + Macugen (Pegaptanib) | Pfizer | Pre-clinical | 22 |
| Macugen ® (pegaptanib sodium) | Pfizer | Approved | 84 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 51 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 51 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 32 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 32 |
| Aflibercept | Regeneron Pharmaceuticals | Phase 2 | 51 |
| 2-mg Intravitreous Aflibercept Injection | Regeneron Pharmaceuticals | Phase 2/3 | 64 |